Delphinus Medical Technologies Appoints Scott A. White as New CEO
Long-time CEO Mark J. Forchette to retireNOVI, Mich.--(BUSINESS WIRE)--#SoftVue--Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™...
Long-time CEO Mark J. Forchette to retireNOVI, Mich.--(BUSINESS WIRE)--#SoftVue--Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™...
THANC Guide resource center for thyroid, head and neck cancer patients will now feature Carebox Connect for clinical trial search...
The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or...
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent...
Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose...
– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed...
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on...
Toronto, Ontario--(Newsfile Corp. - October 3, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to announce the...
PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST DTCs linked to cancer relapse even after prolonged remissionDTCs...
Mevion and RaySearch re-imagine novel solutions to advance the use of emerging proton therapy technologies and empower medical providers to...
NMDP/Be The Match and the CIBMTR, leaders in Cell Therapy research, provide the award to support future leaders and accelerate...
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early...
Expands Clade’s pipeline and broadens its platform with:- proprietary gamma/delta (g/d) TCR universal targeting platform technology,- g/d TCR candidate integrated...
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa...
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CESTPARIS and CAMBRIDGE, Mass., Sept. 29, 2023...
Combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early...
Launches Global Partnership With Know Your Lemons, Will Ring Nasdaq Opening Bell for 17th TimeMARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #bcam--Hologic, Inc. (Nasdaq:...
TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical...
If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two...